



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, August 5th, 2021 1:00 - 5:00 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; William Origer, MD, FAAFP; Mark Helm, MD, MBA, FAAP; Robin Moody, MPH; Caryn Mickelson, PharmD; Cathy Zehrung, RPh; Patrick DeMartino, MD; Cat Livingston, MD, MPH

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Richard Holsapple, RPh; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Megan Herink, PharmD; Dee Weston, JD; Brandon Wells; Amanda Parrish, LCSW; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH

Audience: Andrew Yu, Novartis; Becky Gonzales, ViiV Healthcare; Brandie Feger, Advanced Health; **Brandon Yip, Sanofi-Genzyme***; Chris Yates, Merck; Dennis Schaffner, Sanofi-Genzyme; Erica Kearns; Jody Legg, Mirum Pharmaceuticals; Katie Scheelar, Moda/EOCCO; Kelly Maynard; Kelli Hoang; Kevin Hinthorne, LEO Pharma; Laura Jeffcoat, AbbVie; Leta Evaskus; Margaret Olmon, PharmD, AbbVie; Mark Kantor, AllCare CCO; Matt Worthy, OHSU; Matthew Wright, Artia Solutions; Mike Donabedian, Sarepta Therapeutics; Paul Thompson, Alkermes; Rachel Hartman, IHN CCO; Roy Lindfield, Sunovion; Ryan Rodriguez; **Sophia Yun, Janssen***; Terra Stone, Viiv Healthcare; **Tracy Copeland, Sarepta***; Trent Taylor, Johnson & Johnson; **Jonathan Frochtzawaj, Cascade AIDS Project***

(*) Provided verbal testimony

Written testimony: Posted to OSU Website

I.

CALL TO ORDER

- A. The meeting was called to order at approximately 1:05 pm. Introductions were made by Committee members and staff
- B. Conflict of Interest Declaration - No new conflicts of interest were declared
- C. Approval of June 2020 minutes presented by Mr. Citron
ACTION: Motion to approve, 2nd, all in favor
- D. Department Update provided by Trevor Douglass
- E. Legislative Update provided by Trevor Douglass

II. CONSENT AGENDA TOPICS

- A. CMS Annual Report
- B. Quarterly Utilization Reports
- C. Oncology Prior Authorization Updates
ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

- A. ProDUR Report: Lan Starkweather, PharmD
- B. RetroDUR Report: Dave Engen, PharmD
- C. Oregon State Drug Review: Kathy Sentena, PharmD
 - Antidepressant Review
 - Bipolar Disorder: Resources for primary care providers

IV. PREFERRED DRUG LIST NEW BUSINESS

- A. **SGLT-2 Inhibitors Class Update:** Kathy Sentena, PharmD
Recommendations:
 - No changes to the PDL based on clinical evidence
 - Evaluate costs in executive session**ACTION:** The Committee recommended to no longer require PA for preferred SGLT-2 inhibitors
Motion to approve, 2nd, all in favor

- B. **Amondys 45™ (casimersen) New Drug Evaluation:** Sarah Servid, PharmD
Recommendation:

- Update PA criteria for DMD to include casimersen

Public Comment: Tracy Copeland, Sarepta Therapeutics

ACTION: Motion to approve, 2nd, all in favor

C. **Benlysta® (belimumab) Prior Authorization Update:** Deanna Moretz, PharmD

Recommendation:

- Update the PA criteria for belimumab to include the expanded FDA indication for adults with active lupus nephritis

ACTION: Motion to approve, 2nd, all in favor

D. **Other Dyslipidemia Drugs Class Update and New Drug Evaluation:**

Megan Herink, PharmD

Recommendations:

- Make Evkeeza™ (evinacumab) non-preferred and require PA to limit use to patients with homozygous familial hypercholesterolemia (HoFH) requiring additional LDL-lowering on maximally tolerated lipid lowering therapies
- Evaluate costs in executive session

ACTION: The Committee wanted a statement included: that the safety and efficacy is unproven, but nonetheless they approve the proposed recommendations

Motion to approve, 2nd, all in favor

E. **Overactive Bladder Class Update and New Drug Evaluation:** Kathy Sentena, PharmD

Recommendations:

- Maintain vibegron as non-preferred on the PDL
- No changes to the PDL bases on clinical evidence
- Evaluate costs in executive session

ACTION: The Committee recommended to no longer require PA for preferred SGLT-2 inhibitors

Motion to approve, 2nd, all in favor

F. **Asthma Biologics DERP Summary:** Deanna Moretz, PharmD

Recommendations:

- No changes to the PDL bases on clinical evidence
- Create a PDL class entitled “Biologics for Severe Asthma” and include benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab
- Modify “Monoclonal Antibodies for Severe Asthma” PA criteria to include expanded indications
- Retire current dupilumab PA criteria and add dupilumab to “Monoclonal Antibodies for Severe Asthma” PA criteria

- Apply PA criteria to physician administered drugs for all monoclonal antibodies used to treat asthma

- Evaluate costs in executive session

Public Comment: Brandon Yip, Sanofi Genzyme

ACTION: Motion to approve, 2nd, all in favor

G. Phosphate Binders Literature Scan: Deanna Moretz, PharmD

Recommendations:

- No changes to the PDL based on clinical evidence
- Remove PA requirement for preferred non-calcium products
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

H. HIV Class Update and New Drug Evaluation:

Sara Fletcher, PharmD & Andrew Gibler, PharmD

Recommendations:

- No changes to the PDL or current policy based on clinical evidence
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

V. EXECUTIVE SESSION

Members Present Stacy Ramirez, PharmD; William Origer, MD, FAAFP; Mark Helm, MD, MBA, FAAP; Robin Moody, MPH; Caryn Mickelson, PharmD, Cathy Zehring, PharmD; Patrick DeMartino, MD; Cat Livingston, MD, MPH

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Kathy Sentena, PharmD; Richard Holsapple, RPh; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan Herink, PharmD; Dee Weston, JD; Brandon Wells; Amanda Parrish, LCSW; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. SGLT-2 Inhibitors Class Update:

Recommendation: No PDL changes recommended

ACTION: Motion to approve, 2nd, 6 in-favor and 2 opposed

B. Other Dyslipidemia Drugs Class Update and New Drug Evaluation:

Recommendation: No PDL changes recommended

ACTION: Motion to approve, 2nd, all in favor

C. **Overactive Bladder Class Update and New Drug Evaluation**

Recommendation: Make solifenacin succinate tables preferred on the PDL

ACTION: Motion to approve, 2nd, all in favor

D. **Asthma Biologics DERP Summary:**

Recommendation: No PDL changes recommended

ACTION: Motion to approve, 2nd, all in favor

E. **Phosphate Binders Literature Scan**

Recommendation: Make sevelamer carbonate tables preferred on the PDL

ACTION: Motion to approve, 2nd, all in favor

F. **HIV Class Update and New Drug Evaluation**

Recommendation: No PDL changes recommended

ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN